Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]

Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)] Publisher Pubmed

Dadras P¹ ; Atyabi F^{1, 2} ; Irani S³ ; Mamani L⁴ ; Foroumadi A⁵ ; Mirzaie ZH⁶ ; Ebrahimi M⁷ ; Dinarvand R^{1, 2}

Show Affiliations

1. Dept. of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14174, Iran
2. Dept. of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14174, Iran
3. Dept. of Biology, Science and Research Branch, Islamic Azad University, Tehran, 14638-45581, Iran
4. Dept. of Nanotechnology, Agricultural Biotechnology Research Institute of Iran (ABRII), Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
5. Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14155-6451, Iran
6. Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14174, Iran
7. Dept. of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

Source: European Journal of Pharmaceutical Sciences Published:2022

Abstract

The authors regret to report about an inadvertent mistake happened to figure 1B of this paper. The TEM micrograph of SPION loaded PLGA nanoparticles containing docetaxel and silibinin (DTX/SIL/SPION@PLGA NPs) of figure 1B is not correct and should be replaced with below figure 1B. The authors would like to apologise for any inconvenience caused. © 2022 Elsevier B.V.

Style	Citing Format
MLA	Dadras P, et al.. "Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]." European Journal of Pharmaceutical Sciences, vol. 179, no. , 2022, pp. -.
APA	Dadras P, Atyabi F, Irani S, Mamani L, Foroumadi A, Mirzaie ZH, Ebrahimi M, Dinarvand R (2022). Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]. European Journal of Pharmaceutical Sciences, 179(), -.
Chicago	Dadras P, Atyabi F, Irani S, Mamani L, Foroumadi A, Mirzaie ZH, Ebrahimi M, Dinarvand R. "Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]." European Journal of Pharmaceutical Sciences 179, no. (2022): -.
Harvard	Dadras P et al. (2022) 'Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]', European Journal of Pharmaceutical Sciences, 179(), pp. -.
Vancouver	Dadras P, Atyabi F, Irani S, Mamani L, Foroumadi A, Mirzaie ZH, et al.. Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]. European Journal of Pharmaceutical Sciences. 2022;179():-.
BibTex	@article{ author = {Dadras P and Atyabi F and Irani S and Mamani L and Foroumadi A and Mirzaie ZH and Ebrahimi M and Dinarvand R}, title = {Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]}, journal = {European Journal of Pharmaceutical Sciences}, volume = {179}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Dadras P AU - Atyabi F AU - Irani S AU - Mamani L AU - Foroumadi A AU - Mirzaie ZH AU - Ebrahimi M AU - Dinarvand R TI - Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)] JO - European Journal of Pharmaceutical Sciences VL - 179 IS - SP - EP - PY - 2022 ER -

Style

Citing Format

MLA

Dadras P, et al.. "Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]." European Journal of Pharmaceutical Sciences, vol. 179, no. , 2022, pp. -.

APA

Dadras P, Atyabi F, Irani S, Mamani L, Foroumadi A, Mirzaie ZH, Ebrahimi M, Dinarvand R (2022). Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]. European Journal of Pharmaceutical Sciences, 179(), -.

Chicago

Dadras P, Atyabi F, Irani S, Mamani L, Foroumadi A, Mirzaie ZH, Ebrahimi M, Dinarvand R. "Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]." European Journal of Pharmaceutical Sciences 179, no. (2022): -.

Harvard

Dadras P et al. (2022) 'Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]', European Journal of Pharmaceutical Sciences, 179(), pp. -.

Vancouver

Dadras P, Atyabi F, Irani S, Mamani L, Foroumadi A, Mirzaie ZH, et al.. Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]. European Journal of Pharmaceutical Sciences. 2022;179():-.

BibTex

@article{ author = {Dadras P and Atyabi F and Irani S and Mamani L and Foroumadi A and Mirzaie ZH and Ebrahimi M and Dinarvand R}, title = {Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]}, journal = {European Journal of Pharmaceutical Sciences}, volume = {179}, number = {}, pages = {-}, year = {2022} }

RIS

TY - JOUR
AU - Dadras P
AU - Atyabi F
AU - Irani S
AU - Mamani L
AU - Foroumadi A
AU - Mirzaie ZH
AU - Ebrahimi M
AU - Dinarvand R
TI - Corrigendum To: Formulation and Evaluation of Targeted Nanoparticles for Breast Cancer Theranostic System [European Journal of Pharmaceutical Sciences, 97 (2017) 47-54, (S0928098716304845), (10.1016/J.Ejps.2016.11.005)]
JO - European Journal of Pharmaceutical Sciences
VL - 179
IS -
SP -
EP -
PY - 2022
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract